Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 3
2014 6
2015 3
2016 7
2017 12
2018 20
2019 24
2020 39
2021 93
2022 95
2023 105
2024 118
2025 131
2026 70

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

652 results

Results by year

Filters applied: . Clear all
Page 1
Dapagliflozin in Patients with Chronic Kidney Disease.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. N Engl J Med. 2020. PMID: 32970396 Free article. Clinical Trial.
BACKGROUND: Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not kn …
BACKGROUND: Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. …
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefánsson BV, Langkilde AM, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Chertow GM, et al. J Am Soc Nephrol. 2021 Sep;32(9):2352-2361. doi: 10.1681/ASN.2021020167. Epub 2021 Jul 16. J Am Soc Nephrol. 2021. PMID: 34272327 Free PMC article. Clinical Trial.
BACKGROUND: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney …
BACKGROUND: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomi …
Prevalence of Chronic Kidney Disease in China: Results From the Sixth China Chronic Disease and Risk Factor Surveillance.
Wang L, Xu X, Zhang M, Hu C, Zhang X, Li C, Nie S, Huang Z, Zhao Z, Hou FF, Zhou M. Wang L, et al. JAMA Intern Med. 2023 Apr 1;183(4):298-310. doi: 10.1001/jamainternmed.2022.6817. JAMA Intern Med. 2023. PMID: 36804760 Free PMC article.
IMPORTANCE: To our knowledge, there has been no update on the prevalence of chronic kidney disease (CKD) in China since 2012. OBJECTIVE: To provide periodic nationwide data on the prevalence of CKD and the associated behavioral and metabolic risk factors in C …
IMPORTANCE: To our knowledge, there has been no update on the prevalence of chronic kidney disease (CKD) in China since …
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, Sjöström CD, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Wheeler DC, et al. Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7. Lancet Diabetes Endocrinol. 2021. PMID: 33338413 Clinical Trial.
BACKGROUND: Dapagliflozin reduces the risk of kidney failure and heart failure in patients with chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney, cardiovascular, and mortality outcomes accordin …
BACKGROUND: Dapagliflozin reduces the risk of kidney failure and heart failure in patients with chronic kidney …
The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis.
McEwan P, Gabb PD, Davis JA, Garcia Sanchez JJ, Sjöström CD, Barone S, Kashioulis P, Ouwens M, Cassimaty S, Correa-Rotter R, Rossing P, Wheeler DC, Heerspink HJL. McEwan P, et al. Nephrol Dial Transplant. 2024 Nov 27;39(12):2040-2047. doi: 10.1093/ndt/gfae106. Nephrol Dial Transplant. 2024. PMID: 38730538 Free PMC article. Clinical Trial.
BACKGROUND: Chronic kidney disease (CKD) presents a significant clinical and economic burden to healthcare systems worldwide, which increases considerably with progression towards kidney failure. The Dapagliflozin and Prevention of Adverse Outco …
BACKGROUND: Chronic kidney disease (CKD) presents a significant clinical and economic burden to healthcare systems worl …
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Jongs N, et al. Lancet Diabetes Endocrinol. 2021 Nov;9(11):755-766. doi: 10.1016/S2213-8587(21)00243-6. Epub 2021 Oct 4. Lancet Diabetes Endocrinol. 2021. PMID: 34619106 Clinical Trial.
BACKGROUND: Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes and …
BACKGROUND: Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic …
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Greene T; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. Lancet Diabetes Endocrinol. 2021 Nov;9(11):743-754. doi: 10.1016/S2213-8587(21)00242-4. Epub 2021 Oct 4. Lancet Diabetes Endocrinol. 2021. PMID: 34619108 Clinical Trial.
BACKGROUND: Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. ...INTERPRETATION: Dapagliflozin significantly slowed long-term eGFR decline in p …
BACKGROUND: Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with …
Dapagliflozin for the treatment of chronic kidney disease.
Kurata Y, Nangaku M. Kurata Y, et al. Expert Rev Endocrinol Metab. 2022 Jul;17(4):275-291. doi: 10.1080/17446651.2022.2099373. Epub 2022 Jul 13. Expert Rev Endocrinol Metab. 2022. PMID: 35822873 Review.
SGLT2 inhibitors (SGLT2is), initially developed as an antidiabetic drug, have recently attracted considerable attention because they have cardiorenal protective effects. Among SGLT2is, dapagliflozin was the first to demonstrate the renoprotective effect in patients with an …
SGLT2 inhibitors (SGLT2is), initially developed as an antidiabetic drug, have recently attracted considerable attention because they have ca …
Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.
Yu MK, Vart P, Jongs N, Correa-Rotter R, Rossing P, McMurray JJV, Hou FF, Douthat W, Khullar D, Langkilde AM, Wheeler DC, Heerspink HJL, Chertow GM. Yu MK, et al. J Gen Intern Med. 2024 May;39(6):921-930. doi: 10.1007/s11606-023-08397-9. Epub 2023 Dec 14. J Gen Intern Med. 2024. PMID: 38097862 Free PMC article. Clinical Trial.
BACKGROUND: The sodium-glucose cotransporter type 2 inhibitor dapagliflozin reduces the risk of progressive kidney disease and cardiovascular events in patients with chronic kidney disease, with and without type 2 diabetes. ...PARTICIPANT …
BACKGROUND: The sodium-glucose cotransporter type 2 inhibitor dapagliflozin reduces the risk of progressive kidney disease …
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
Provenzano M, Puchades MJ, Garofalo C, Jongs N, D'Marco L, Andreucci M, De Nicola L, Gorriz JL, Heerspink HJL; ROTATE-3 study group; ROTATE-3 study group members. Provenzano M, et al. J Am Soc Nephrol. 2022 Aug;33(8):1569-1580. doi: 10.1681/ASN.2022020207. Epub 2022 Apr 19. J Am Soc Nephrol. 2022. PMID: 35440501 Free PMC article. Clinical Trial.
UACR change during dapagliflozin or eplerenone treatment did not correlate with UACR change during dapagliflozin-eplerenone (r=-0.13; P=0.47; r=-0.08; P=0.66, respectively). Hyperkalemia was more frequently reported with eplerenone (n=8; 17.4%) compared with dapa …
UACR change during dapagliflozin or eplerenone treatment did not correlate with UACR change during dapagliflozin-eplerenone (r …
652 results